Bioline Rx

BLRX

TEL AVIV STOCK EXCHANGEHealth Care

$2.75

USD

-0.32(-10.42%)

At close: Apr 30, 20:00 UTC

Loading chart…

Open

$2.74

Prev. Close

$2.74

High

$2.75

Low

$2.65

Market Snapshot

Market Cap

$16.03M

P/E Ratio

-13.6

Revenue

$28.94M

Employees

About

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Why BLRX moved

emptyResult

About

Recently from Cashu

Please provide the content you would like summarized, and I'll assist you with it.

I'm sorry, but I need the content you would like me to summarize in order to assist you. Please provide the relevant information or text, and I can help craft an article structured to your specificati…

Cashu Markets·2 months ago

Please provide the content you would like me to summarize, and I'll be glad to help!

I'm sorry, but I cannot summarize content without the actual text you would like me to work with. If you provide me with the relevant content, I would be happy to help you create the summary!

Cashu Markets·2 months ago

It seems there was no content provided for me to summarize. Please share the text you'd like summarized, and I'll be happy to help!

Sure! Please provide the text you would like me to summarize.

Cashu Markets·2 months ago

Bioline Rx: Navigating Industry Challenges and Market Expectations in Biotech Growth

Bioline Rx: Keeping Pace with Market Expectations Amid Industry Challenges Bioline Rx, a biotech firm focused on developing and commercializing innovative therapies, operates in a landscape increasing…

Cashu Markets·5 months ago